Log in to save to my catalogue

Efficacy, Safety, and Immunogenicity of Biosimilar Adalimumab Advixa® Compared With Reference Produc...

Efficacy, Safety, and Immunogenicity of Biosimilar Adalimumab Advixa® Compared With Reference Produc...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11832712

Efficacy, Safety, and Immunogenicity of Biosimilar Adalimumab Advixa® Compared With Reference Product Humira® in Patients With Rheumatoid Arthritis in Bangladesh

About this item

Full title

Efficacy, Safety, and Immunogenicity of Biosimilar Adalimumab Advixa® Compared With Reference Product Humira® in Patients With Rheumatoid Arthritis in Bangladesh

Publisher

United States: Springer Nature B.V

Journal title

Curēus (Palo Alto, CA), 2025-01, Vol.17 (1), p.e77638

Language

English

Formats

Publication information

Publisher

United States: Springer Nature B.V

More information

Scope and Contents

Contents

This study evaluated the efficacy, safety, and immunogenicity of biosimilar adalimumab drug Advixa® (Incepta Pharmaceuticals Ltd, Dhaka, Bangladesh) in patients with moderate to severe rheumatoid arthritis (RA) compared to the reference drug Humira® (AbbVie Inc., North Chicago, IL, USA).
In this randomized, double-blind, prospective, parallel-gr...

Alternative Titles

Full title

Efficacy, Safety, and Immunogenicity of Biosimilar Adalimumab Advixa® Compared With Reference Product Humira® in Patients With Rheumatoid Arthritis in Bangladesh

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11832712

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11832712

Other Identifiers

ISSN

2168-8184

E-ISSN

2168-8184

DOI

10.7759/cureus.77638

How to access this item